Evidence map›Paper›PMID 40753178›Full record

ArticleCell death & disease2025

Enlarged PML-nuclear bodies trigger conflicting cell cycle signal-mediated cytotoxicity in leukemia cells.

Tomohisa Baba, Soichiro Kumamoto, Yuta Moriguchi, Soji Morishita, Atsushi Hirao, Yoshikazu Johmura

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomohisa Baba *Division of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan. sergenti@staff.kanazawa-u.ac.jp.ORCID http://orcid.org/0000-0002-2161-2087
Soichiro Kumamoto *Division of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID http://orcid.org/0000-0002-3492-117X
Yuta MoriguchiDivision of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID http://orcid.org/0009-0003-7784-5589
Soji MorishitaDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1081-0130
Atsushi HiraoDivision of Molecular Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID http://orcid.org/0000-0001-7818-8240
Yoshikazu JohmuraDivision of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID http://orcid.org/0000-0002-6812-9607

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 23H03835MEXT | Japan Society for the Promotion of Science (JSPS) 23K27376MEXT | Japan Society for the Promotion of Science (JSPS) 24K11555
6 · The paper itself

Abstract

Accumulating evidence suggests that mitogenic signaling during cell cycle arrest can lead to severe cytotoxic outcomes, such as senescence, though the underlying mechanisms remain poorly understood. Here, we explored the link between cell cycle dynamics and the formation of PML-nuclear bodies (PML-NBs), intranuclear structures known to mediate cellular stress responses. Our findings demonstrate that PML-NBs increase their number during interphase arrest. Moreover, the activation of mitogenic ERK signaling by all-trans retinoic acid (ATRA) during CDK4/6 inhibitor-induced cell cycle arrest synergistically enhances the formation of larger PML-NBs by associating with SUMO. This enlargement, triggered by the simultaneous engagement of opposing cell cycle signals, leads to potent cytotoxicity accompanied by either terminal differentiation or apoptosis, depending on the cell type, across multiple acute myeloid leukemia (AML) cell lines. Importantly, in an AML mouse model, this combination treatment significantly improved therapeutic efficacy with minimal effects on normal hematopoiesis. Our results introduce conflicting cell cycle signal-induced cytotoxicity as a promising therapeutic strategy for AML.

Indexed as

Intranuclear Inclusion BodiesLeukemia, Myeloid, AcutePromyelocytic Leukemia ProteinAnimalsApoptosisCell CycleCell Cycle CheckpointsCell Line, TumorHumansMiceSignal TransductionTretinoinPML protein, humanPromyelocytic Leukemia ProteinTretinoin

Identifiers

PMID40753178
PMCPMC12318136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.